Insider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 100,000 Shares of Stock

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Director Wei-Wu He bought 100,000 shares of CASI Pharmaceuticals stock in a transaction on Tuesday, October 10th. The shares were bought at an average price of $1.95 per share, for a total transaction of $195,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Wei-Wu He also recently made the following trade(s):

  • On Friday, October 6th, Wei-Wu He bought 200,000 shares of CASI Pharmaceuticals stock. The shares were bought at an average price of $1.83 per share, for a total transaction of $366,000.00.
  • On Monday, September 18th, Wei-Wu He bought 173,500 shares of CASI Pharmaceuticals stock. The shares were bought at an average price of $1.75 per share, for a total transaction of $303,625.00.
  • On Tuesday, September 19th, Wei-Wu He bought 207,502 shares of CASI Pharmaceuticals stock. The shares were bought at an average price of $1.75 per share, for a total transaction of $363,128.50.
  • On Friday, September 15th, Wei-Wu He bought 315,327 shares of CASI Pharmaceuticals stock. The shares were bought at an average price of $1.33 per share, for a total transaction of $419,384.91.

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) traded up 47.75% during midday trading on Wednesday, hitting $3.28. The stock had a trading volume of 18,870,471 shares. CASI Pharmaceuticals, Inc. has a 52 week low of $0.91 and a 52 week high of $4.84. The stock’s market capitalization is $197.44 million. The company’s 50 day moving average price is $1.43 and its 200-day moving average price is $1.16.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Equities analysts anticipate that CASI Pharmaceuticals, Inc. will post ($0.15) earnings per share for the current fiscal year.

WARNING: “Insider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 100,000 Shares of Stock” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://sportsperspectives.com/2017/10/11/insider-buying-casi-pharmaceuticals-inc-casi-director-purchases-100000-shares-of-stock.html.

A number of brokerages have issued reports on CASI. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of CASI Pharmaceuticals in a report on Friday, September 8th. Maxim Group set a $4.00 target price on CASI Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 14th. Finally, ValuEngine cut CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, July 22nd.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply